Navigation Links
NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinson's Disease
Date:10/6/2010

NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the... -- NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Financing Agreements, Awards, Not For Profit Click to view news release full screen  

NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinson's Disease

 

NESS ZIONA, Israel, October 6, 2010 /PRNewswire/ -- NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

ND0611 is a proprietary drug formula that enables, for the first time, the continuous administration of carbidopa via a sub-cutaneous dermal patch. Carbidopa is conventionally administered orally with levodopa to prevent its breakdown. In pre-clinical studies, plasma levodopa concentration profiles showed markedly less fluctuation after continuous administration of ND0611. The levodopa area-under-the-curve values and trough concentrations were greatly increased when ND0611 was administered together with standard levodopa products (Sinemet(R), Stalevo(R) and Sinemet(R) CR). This effect was achieved through an as-yet unclear mode of action that may involve a novel levodopa metabolic pathway. Subcutaneous carbidopa delivery may permit more continuous levels of levodopa to be maintained in the brain, thus helping to manage motor fluctuations in Parkinson's disease patients.

"The enormous show of confidence by The Michael J. Fox Foundation for Parkinson's Research in this new therapeutic approach for Parkinson's disease strengthens our efforts to develop innovative treatments for the many unmet needs of patients with this disorder," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "It also underscores NeuroDerm's deep commitment and expertise in the development of novel therapeutics for diseases of the central nervous system."

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops novel therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well established oral drugs, whose low bio-availability is the major impediment to better efficacy. The company's lead product is ND0611, a revolutionary skin patch for the treatment of Parkinson's disease. Other products for the treatment of various diseases, including ADD, ADHD, schizophrenia and Alzheimer's disease, are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

Contact: Oded S. Lieberman, PhD MBA, Chairman & CEO oded@neuroderm.com Tel.: +972-8-946 2729; Cell: +1-617-517 6077
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Dr. Yong Shi awarded NSF grant
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
7. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
8. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
9. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
10. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
11. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):